Context Testosterone replacement therapy is the standard treatment for male hypogonadism. There has lately been increased marketing in the medical media promoting testosterone replacement for men with erectile dysfunction or for older men with low serum testosterone, despite the lack of long-term safety and efficacy data. Therefore, we aimed to examine trends in testosterone prescribing in UK primary care over the last 10 years. Methods Data about the use of testosterone preparations from the Departments of Health Prescription Cost Analysis for community pharmacies 2001-2010, for England, Scotland and Wales, were collated. Community requests for serum total testosterone assay in men to the Biochemistry Department at the Newcastle upon Tyne Hospitals Trust were also examined over the same time period. Results The number of prescriptions for testosterone preparations increased by nearly 90% from 157 602 to 298 134 dispensed items annually, over a 10-year period. However, due to a particularly significant (fivefold) increase in prescribing of (more expensive) transdermal preparations, the cost to the NHS showed a 267% escalation, from £3Á2 to £11Á7 million, annually over the same period. Local requests from primary care in the Newcastle and North Tyneside area for serum testosterone measurement in men also increased, from 347 requests in 2000 to 823 requests in 2010, a 137% increase. However, the number of men with likely unequivocal hypogonadism (testosterone less than 6Á0 nM) remained constant at 5Á2% in 2000 and 6Á3% in 2010. Conclusion Many men in the UK might be receiving testosterone replacement therapy with neither clearly established indications nor robustly diagnosed hypogonadism. A national registry for men treated with testosterone and further evidence to improve current guidance (national and/or international) on the indications for testosterone replacement would be beneficial.
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Background
Human efforts to restore virility and to reverse the effects of ageing in men have been documented since ancient times. As early as 1849, Adolph Berthold postulated a connection between testicular secretions and male behavioural and sexual characteristics from his testicular transplantation experiments. 1 When testosterone was chemically synthesized in 1935, it marked the beginning of a new era in men's health. While the only validated indication for testosterone treatment is male hypogonadism with pathological androgen deficiency, there has been an increasing focus on its role as a 'function-promoting' therapy in older or obese men who wish to restore virility or male character, despite the lack of sound clinical evidence to support this practice. Male hypogonadism is a clinical syndrome resulting from failure of the testis to produce physiological levels of testosterone and/or maintain normal spermatogenesis, due to disruption of one or more levels of the hypothalamicpituitary-testis (HPT) axis. Features of hypogonadism include sexual dysfunction, loss of muscle bulk, central obesity, fatigue and mood/sleep disturbances. Long-term complications such as osteoporosis, low-impact fracture and chronic anaemia occur in untreated cases. 2 Although these features are all associated with low serum testosterone concentration, not all men with a low serum testosterone have organic hypogonadism, and there is a large symptom overlap with obesity and nonendocrine illness. For instance, obesity is associated with progressively lower total and free serum testosterone independent of simultaneous reductions in sex hormone binding globulin (SHBG). Lower luteinizing hormone (LH) levels are also seen in obese men, suggesting a potential failure in the hypothalamuspituitary level. 3 Additionally, the HPT axis exhibits diurnal variation in activity and tends to physiologically shutdown with any form of acute stress, including strenuous physical exertion and sleep deprivation, 4 or chronic disease, such as depression, malnutrition and obesity. There is even an acute suppressive effect of oral glucose loading. 5 Importantly, the HPT axis invariably recovers once these modifiable factors are corrected, 6 hence our preferred term 'functional' hypogonadotropic hypotestosteronaemia (FHH) of nongonadal illness.
Chronic use of prescription and/or nonprescription drugs can also induce hypogonadism, mostly through HPT axis suppression, including opioids, 7 tricyclic antidepressants and selective serotonin reuptake inhibitors, 8 antidopaminergic drugs with hyperprolactinaemic effect such as phenothiazines 8 and risperidone, 9 and antiandrogens such as spironolactone, finasteride 10 and synthetic androgens/anabolic steroids. 11 
Local community requests for serum total testosterone assay in men 2000-2010
The number of primary care requests from 2000 to 2010, inclusive, for total testosterone assay in men to the Biochemistry 
2003.
The PCA data in England also revealed that the use of testosterone undecanoate has been on the rise over the past 10 years, from 31 336 to 65 998 items (111%; [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] . This is solely attributed to the introduction of long-acting testosterone depot injection, Nebido â (Bayer Schering), for which there has been a 
Analysis of local community requests for serum total testosterone assay in men 2000-2010
Local requests for serum testosterone measurement in men from primary care in the NuTH Biochemistry Department have increased from 347 requests in 2000 to 823 requests in 2010, with a 137% rise (Fig. 3, panel a) . However, the number of men with a high likelihood of hypogonadism (testosterone less than 6Á0 nM) remained relatively constant at 5Á2% in 2000 and 6Á3% in 2010. On the other hand, the number of men with total testosterone in the 6-8Á9 nM range, where there is greater uncertainty in the diagnosis of hypogonadism, increased by over 2-fold, from 7Á51% to 16Á99%. (Fig. 3, panel b ).
Discussion
The PCA data from England, Wales and Scotland have clearly shown a progressive rise in the prescribing of testosterone from 2001-2010. This is in keeping with the data available globally, including Switzerland, 19 United States 20 and Australia, 21 suggesting a potential 'pandemic' of testosterone prescribing. There are a number of potential explanations for this trend. Firstly, conditions associated with hypogonadism might be on the rise. Trend of serum testosterone level from GP requests at Royal Victoria Infirmary, Newcastle upon Tyne ized for seminoma or teratoma of the testis. Finally, opioids such as tramadol and slow-released morphine sulphate tablets are now more widely used for the treatment of chronic noncancer pain. However, the nearly twofold increase in testosterone prescribing is highly unlikely to be solely attributable to an increased prevalence of male hypogonadism, especially as most men with KS, the commonest cause of pathological male hypogonadism, only become hypogonadal later in life. 24 Another possible explanation for the observed prescribing trend is increased testosterone testing in primary care, which could potentially result in either improved diagnosis of male hypogonadism and/or an unwarranted increase in TRT in men with borderline serum testosterone concentrations. It is entirely appropriate to treat symptomatic men with borderline-low testosterone under defined circumstances, such as gonadotrophin deficiency resulting from pituitary tumours or prescribed opiate analgesia, or elevated gonadotrophins diagnostic of primary testicular dysfunction (e.g. KS). However, with these important exceptions, there is insufficient evidence for initiating TRT in most men with a borderlinelow serum testosterone due to FHH. There are likewise no data to support testosterone therapy in the context of age-related frailty. 3, 25, 26 We simply do not know whether borderline biochemical hypotestosteronaemia related to FHH is maladaptive, neutral or conceivably even adaptive.
Our local survey has demonstrated that the absolute number of men with likely unequivocal hypogonadism (testosterone <6Á0 nM) has remained relatively constant despite a surge in testosterone testing in primary care. The rising number of requests has identified significantly more men with testosterone level in the 6-9 nM range, although 9 nM is the lower limit of the adult male normal range in our assay. Admittedly, this local pattern of requests and results might not reflect the overall situation in the UK, but there are currently no other comparable published data available.
Finally, a plausible explanation for the observed trend in testosterone prescribing in the UK is that an increasing number of eugonadal men might be receiving unnecessary testosterone therapy, particularly older men with 'nongonadal' illness. Although the newer testosterone preparations have undoubtedly improved the quality of life for many men with organic hypogonadism, due to ease of use and better pharmacokinetic profile, pharma has promoted TRT to a broader population of older men with sexual dysfunction. 27, 28 Over the past 3 years, the advertising tracker Kantar Media has reported an increase of more than 170% in spending on advertising by pharmaceutical companies such as Abbott and Eli Lilly in the USA to promote TRT.
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Although direct-to-consumer pharmaceutical marketing is not permitted in the UK, the public has virtually unfettered access to pharma websites as key sources of information relating to ageing, erectile dysfunction and the 'andropause'. [30] [31] [32] [33] A general theme from pharma-hosted online sources is that testosterone deficiency is common and particularly so with advancing age. Hence, it should be no surprise if men with nonspecific, physiological, age-or illness-related symptoms should increasingly consider these as possible manifestations of testosterone deficiency, with a consequent belief that TRT might restore their quality of life and virility. The question is whether this information campaign has over-reached the actual evidence? It is well established that a significant portion of older men have testosterone levels below the lower limit for healthy, young men, with an average decline in serum testosterone levels of 1-2% per year. 34 Although this has historically been attributed to physiological decline in testosterone production with age, a large 5-year longitudinal study involving 1 382 community-dwelling men reported that the testosterone decline seen in older men was actually largely caused by a combination of an increased burden of nonendocrine disease and modifiable factors, such as obesity and lifestyle, rather than being an inevitable fact of ageing per se.
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Indeed, the Odense Androgen Study demonstrated similar serum testosterone reference intervals for both young and elderly healthy men. 36 In keeping with these studies, the European Male Aging Study (EMAS), a large cross-sectional study involving 3 369 participants, highlighted that many predisposing lifestyle and health factors contributing to the age-related decline in testosterone levels are modifiable and preventable. 26, 37 Overall, these studies do not support the concept of a widespread, inevitable syndrome of age-related sex hormone deficiency in men. The EMAS found a prevalence of late-onset hypogonadism (LOH) of only 2Á1% in the general male population and 5Á1% in men aged 70-79 years, 26 contrasting with a prevalence for LOH of up to 12% quoted by some pharma promotional material. 32 Overall, testosterone levels do not correlate well with the symptoms of hypogonadism in older men with LOH, 26 and there is a lack of compelling evidence from large-scale RCTs on the benefits of TRT in ageing men. [15] [16] [17] [18] While reduced muscle mass and bone mineral density are clearly established features of organic/syndromic hypogonadism, there is inadequate evidence for a causal relationship between the similar physiological changes observed in older men with FHH. Studies of TRT performed in frail older men have given conflicting results in relation to muscle strength, mood, sexual function and quality of life. [15] [16] [17] [18] Moreover, restoring testosterone level in older men to the 'normal range' risks rendering them 'supraphysiologically' replaced. Older men exhibit slower clearance of steroid hormones and are more susceptible to androgen-induced polycythaemia and consequent thrombosis risk, as shown by a meta-analysis including 19 randomized, placebo-controlled studies. 38 Finally, the potential risks of converting a clinically inapparent focus of prostate carcinoma into a more aggressive lesion remain unquantified. There are good data to suggest maintaining thyroid hormone levels at a lower 'normal range' is beneficial for older people, 39 and the same principle might conceivably also hold true for testosterone. For instance, it was shown that aggressive testosterone replacement in frail men aged 65 years and above was associated with a significantly increased rate of cardiovascular events. 25 Therefore, GPs should recognize that many of the proposed beneficial effects ascribed to TRT in older men with putative LOH remain unproven and that the potential long-term risks remain uncharacterized at present. Additionally, there is quantifiable health burden and cost relating to testosterone administration and monitoring such as digital rectal examinations, prostate-specific antigen and haematocrit measurement.
The various guidelines and consensus statements currently available [40] [41] [42] [43] are mostly based on expert committee reports, opinions or small, nonrandomized controlled studies, representing the very lowest category of the evidence-grading scale. They tend not to distinguish very clearly between organic/syndromic hypogonadism (for which there is evidence of benefit from TRT) and age-/comorbidity-related hypotestosteronaemia (FHH, for which there is generally no evidence). Proposed treatment thresholds are therefore arbitrary and necessarily vary between the different guidelines. For instance, the Endocrine Society Clinical Practice Guideline is unprescriptive in relation to testosterone treatment for older men with low serum testosterone concentration and to the exact treatment threshold. 40 However, it does caution against a general policy of offering testosterone therapy to all older men with low testosterone levels, with the decision to treat needing to be made by clinicians on an individual patient basis. Although there is no UK national guideline for testosterone prescribing in men, the Society for Endocrinology has recently issued a valuable position statement on male hypogonadism and ageing. 43 This usefully states that, although TRT has been used effectively for many years in younger patients with classical hypogonadism without major adverse events, the same experience should not be extrapolated to the area of LOH, which is still lacking in longer-term studies of sufficient power to establish clinical outcomes.
Conclusion
These data have provided a unique perspective into current testosterone prescribing trends in UK. It is likely that an increasing number of men in the UK might be receiving testosterone therapy without a clearly established indication, or even without a robust clinical diagnosis of hypogonadism. Importantly, there is a general lack of consensus on the threshold to treat in men presenting with nonspecific symptoms and borderline-low serum testosterone level. The paucity of data available to define the 'age-specific' range for the older men and the threshold to treat in 'LOH' underscore the need for large-scale RCTs (or at least, long-term patient registries) to monitor clinical outcomes. Given the shortcomings of currently available international guidelines, consideration should be given to developing a UK-based national guideline that clearly distinguishes between organic and functional causes of hypotestosteronaemia, rather than attempting to set semi-arbitrary serum testosterone thresholds, potentially building on the Society for Endocrinology's existing excellent position statement. 43 
